EGFR and breast cancer: Because we have previously shown that hyperactivation of the EGFR pathway mimics oncogenic PIK3CA mutations [64], our results would suggest that breast cancers with mutant PIK3CA and AR expression would have a favorable therapeutic response to AR ligand binding.